Candriam S.C.A. Amicus Therapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$11.43 - $14.24 $2.81 Million - $3.5 Million	245,944 Added 44.4%	799,823 $9.42 Million
Q4 2023 Feb 14, 2024	SELL	$9.97 - $14.52 $249,250 - $363,000	-25,000 Reduced 4.32%	553,879 $7.86 Million
Q3 2023 Nov 13, 2023	SELL	$11.78 - $13.86 $1.35 Million - $1.59 Million	-115,000 Reduced 16.57%	578,879 $7.04 Million
Q4 2022 Feb 13, 2023	BUY	$9.89 - $12.7 $247,250 - $317,500	25,000 Added 3.74%	693,879 $8.47 Million
Q3 2022 Nov 10, 2022	SELL	$9.82 - $12.75 $1.67 Million - $2.17 Million	-170,000 Reduced 20.27%	668,879 $6.98 Million
Q2 2022 Aug 03, 2022	BUY	$6.23 - $11.12 $5.23 Million - $9.33 Million	838,879 New	838,879 $9.01 Million
Q2 2021 Jul 20, 2021	SELL	$8.71 - $10.72 $5.36 Million - $6.59 Million	-615,124 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$13.47 - $24.89 $2.11 Million - $3.89 Million	-156,464 Reduced 20.28%	615,124 $14.2 Million
Q3 2020 Oct 19, 2020	BUY	$12.89 - $15.89 $386,700 - $476,700	30,000 Added 4.05%	771,588 $10.9 Million
Q2 2020 Jul 23, 2020	SELL	$8.86 - $15.69 $1.66 Million - $2.95 Million	-187,912 Reduced 20.22%	741,588 $11.2 Million
Q4 2019 Jan 21, 2020	SELL	$7.48 - $10.75 $347,820 - $499,875	-46,500 Reduced 4.76%	929,500 $9,000
Q3 2019 Oct 21, 2019	BUY	$8.02 - $13.25 $721,800 - $1.19 Million	90,000 Added 10.16%	976,000 $8,000
Q2 2019 Aug 01, 2019	BUY	$10.96 - $14.4 $1.64 Million - $2.16 Million	150,000 Added 20.38%	886,000 $11 Million
Q1 2019 May 02, 2019	BUY	$10.04 - $13.92 $1.41 Million - $1.95 Million	140,000 Added 23.49%	736,000 $10 Million
Q4 2018 Feb 14, 2019	BUY	$8.38 - $13.44 $544,700 - $873,600	65,000 Added 12.24%	596,000 $5.71 Million
Q3 2018 Nov 07, 2018	BUY	$11.6 - $16.54 $812,000 - $1.16 Million	70,000 Added 15.18%	531,000 $6.42 Million
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $52,520 - $68,360	-4,000 Reduced 0.86%	461,000 $7.2 Million
Q1 2018 May 09, 2018	SELL	$13.76 - $17.12 $1.04 Million - $1.29 Million	-75,400 Reduced 13.95%	465,000 $6.99 Million
Q4 2017 Feb 07, 2018	BUY	$12.51 - $16.24 $725,580 - $941,919	58,000 Added 12.02%	540,400 $7.78 Million
Q3 2017 Nov 03, 2017	BUY	$11.74 - $15.78 $5.66 Million - $7.61 Million	482,400	482,400 $7.28 Million

Others Institutions Holding FOLD

# of Institutions

313

Shares Held

312M

Call Options Held

516K

Put Options Held

833K

Vanguard Group Inc Valley Forge, PA

28.8M
Shares

$276 Million
0.01% of portfolio
Perceptive Advisors LLC New York, NY

28.1M
Shares

$269 Million
7.83% of portfolio
Black Rock Inc. New York, NY

24.4M
Shares

$234 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

24M
Shares

$230 Million
0.05% of portfolio
Avoro Capital Advisors LLC New York, NY

23.2M
Shares

$222 Million
3.72% of portfolio

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account